A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03978611
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Relatlimab — DRUG
    Specified dose on specified days
  • Ipilimumab — DRUG
    Specified dose on specified days

Study Details

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.

Key Dates

Start date
Dec 9, 2021
Status verified
Jul 2024
Primary completion
Jul 26, 2023
Completion
Jul 26, 2023

Study Design

Enrollment
11 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1: Dose Escalation Phase

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to Follow-up Period (100 days after 34 cycles [1 cycle is of 3 weeks]) ]

Locations (8)

FacilityCityStateZIPSite coordinators
Local Institution - 0023TucsonArizona85724-
Local Institution - 0002Los AngelesCalifornia90033-
Local Institution - 0005Los AngelesCalifornia90033-
Local Institution - 0001Santa MonicaCalifornia90404-
Local Institution - 0015MiamiFlorida33136-
Local Institution - 0004ChicagoIllinois60611-
Local Institution - 0003Ann ArborMichigan48109-
Local Institution - 0008MorristownNew Jersey07960-

Find similar trials in Tucson, AZ

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Local Institution - 0023· Tucson, AZLocal Institution - 0002· Los Angeles, CALocal Institution - 0005· Los Angeles, CALocal Institution - 0001· Santa Monica, CALocal Institution - 0015· Miami, FLLocal Institution - 0004· Chicago, IL

Related Studies